Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UNLOCK - EPIBREAST, a Phase II Study of Prifetrastat (PF-07248144), a KAT6 Inhibitor, Plus Fulvestrant for Advanced HR+/HER2- Breast Cancer, With Biomarkers Analyses

NCT07340619 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT07340619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07340619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UNLOCK - EPIBREAST, a Phase II Study of Prifetrastat (PF-07248144), a KAT6 Inhibitor, Plus Fulvestrant for Advanced HR+/HER2- Breast Cancer, With Biomarkers Analyses
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 18, 2026
Completion date
November 18, 2029
Enrollment
51 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic (stage iv) melanoma